Agios Pharmaceuticals (AGIO) to Release Quarterly Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) will likely be releasing its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect Agios Pharmaceuticals to post earnings of ($1.96) per share and revenue of $12.0590 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, February 12, 2026 at 8:00 AM ET.

Agios Pharmaceuticals Trading Up 0.7%

Shares of AGIO opened at $27.13 on Wednesday. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00. The stock has a market cap of $1.58 billion, a P/E ratio of -3.88 and a beta of 0.91. The company has a 50-day moving average of $27.37 and a two-hundred day moving average of $34.22.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on AGIO. The Goldman Sachs Group cut their price objective on Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a research report on Thursday, November 20th. Wall Street Zen cut Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. HC Wainwright increased their price objective on Agios Pharmaceuticals from $48.00 to $62.00 and gave the company a “buy” rating in a research note on Wednesday, December 24th. Leerink Partners lifted their price objective on Agios Pharmaceuticals from $34.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, December 26th. Finally, Bank of America upped their target price on shares of Agios Pharmaceuticals from $32.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $39.44.

Insider Buying and Selling

In related news, insider James William Burns sold 2,932 shares of the company’s stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the insider owned 31,718 shares of the company’s stock, valued at approximately $859,240.62. This represents a 8.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Cecilia Jones sold 2,932 shares of the stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the transaction, the chief financial officer directly owned 37,394 shares in the company, valued at approximately $1,013,003.46. This represents a 7.27% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 33,303 shares of company stock worth $901,977 over the last ninety days. Insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC acquired a new position in Agios Pharmaceuticals in the first quarter valued at $40,000. Quantbot Technologies LP acquired a new stake in Agios Pharmaceuticals during the third quarter worth about $79,000. Acadian Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals in the 1st quarter worth about $133,000. Quarry LP acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at about $201,000. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Agios Pharmaceuticals by 634.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,440 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 5,563 shares during the period.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.